TY - JOUR
T1 - Quality of life from cytoreductive surgery in advanced ovarian cancer
T2 - Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study
AU - Sundar, Sudha
AU - Cummins, Carole
AU - Kumar, Satyam
AU - Long, Joanna
AU - Arora, Vivek
AU - Balega, Janos
AU - Broadhead, Tim
AU - Duncan, Tim
AU - Edmondson, Richard
AU - Fotopoulou, Christina
AU - Glasspool, Ros
AU - Kolomainen, Desiree
AU - Leeson, Simon
AU - Manchanda, Ranjit
AU - McNally, Orla
AU - Morrison, Jo
AU - Mukhopadhyay, Asima
AU - Paul, Jim
AU - Tidy, John
AU - Wood, Nick
N1 - Funding Information:
SOCQER2 study in the UK was commissioned and funded by the National Institute of Health and Care excellence. The funder had no role in interpretation of results from the study. The SOCQERoOZ study, conducted at Royal Women's Hospital and Peter MacCallum Cancer Centre in Melbourne, received research grant from Australian Society of Gynaecologic Oncologists Inc. The SOCQER2 India study is part funded by the Department of Science Technology, India ‐ UKIERI grant and Jiv Daya Foundation, USA
Publisher Copyright:
© 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
PY - 2022/1/10
Y1 - 2022/1/10
N2 - Objective: To investigate quality of life (QoL) and association with surgical complexity and disease burden after surgical resection for advanced ovarian cancer in centres with variation in surgical approach. Design: Prospective multicentre observational study. Setting: Gynaecological cancer surgery centres in the UK, Kolkata, India, and Melbourne, Australia. Sample: Patients undergoing surgical resection (with low, intermediate or high surgical complexity score, SCS) for late-stage ovarian cancer. Main Outcome Measures: Primary: change in global score on the European Organisation for Research and Treatment of Cancer (EORTC) core quality-of-life questionnaire (QLQ-C30). Secondary: EORTC ovarian cancer module (OV28), progression-free survival. Results: Patients’ preoperative disease burden and SCS varied between centres, confirming differences in surgical ethos. QoL response rates were 90% up to 18 months. Mean change from the pre-surgical baseline in the EORTC QLQ-C30 was 3.4 (SD 1.8, n = 88) in the low, 4.0 (SD 2.1, n = 55) in the intermediate and 4.3 (SD 2.1, n = 52) in the high-SCS group after 6 weeks (p = 0.048), and 4.3 (SD 2.1, n = 51), 5.1 (SD 2.2, n = 41) and 5.1 (SD 2.2, n = 35), respectively, after 12 months (p = 0.133). In a repeated-measures model, there were no clinically or statistically meaningful differences in EORTC QLQ-C30 global scores between the three SCS groups (p = 0.840), but there was a small statistically significant improvement in all groups over time (p < 0.001). The high-SCS group experienced small to moderate decreases in physical (p = 0.004), role (p = 0.016) and emotional (p = 0.001) function at 6 weeks post-surgery, which resolved by 6–12 months. Conclusions: The global QoL of patients undergoing low-, intermediate- and high-SCS surgery improved at 12 months after surgery and was no worse in patients undergoing extensive surgery. Tweetable Abstract: Compared with surgery of lower complexity, extensive surgery does not result in poorer quality of life in patients with advanced ovarian cancer.
AB - Objective: To investigate quality of life (QoL) and association with surgical complexity and disease burden after surgical resection for advanced ovarian cancer in centres with variation in surgical approach. Design: Prospective multicentre observational study. Setting: Gynaecological cancer surgery centres in the UK, Kolkata, India, and Melbourne, Australia. Sample: Patients undergoing surgical resection (with low, intermediate or high surgical complexity score, SCS) for late-stage ovarian cancer. Main Outcome Measures: Primary: change in global score on the European Organisation for Research and Treatment of Cancer (EORTC) core quality-of-life questionnaire (QLQ-C30). Secondary: EORTC ovarian cancer module (OV28), progression-free survival. Results: Patients’ preoperative disease burden and SCS varied between centres, confirming differences in surgical ethos. QoL response rates were 90% up to 18 months. Mean change from the pre-surgical baseline in the EORTC QLQ-C30 was 3.4 (SD 1.8, n = 88) in the low, 4.0 (SD 2.1, n = 55) in the intermediate and 4.3 (SD 2.1, n = 52) in the high-SCS group after 6 weeks (p = 0.048), and 4.3 (SD 2.1, n = 51), 5.1 (SD 2.2, n = 41) and 5.1 (SD 2.2, n = 35), respectively, after 12 months (p = 0.133). In a repeated-measures model, there were no clinically or statistically meaningful differences in EORTC QLQ-C30 global scores between the three SCS groups (p = 0.840), but there was a small statistically significant improvement in all groups over time (p < 0.001). The high-SCS group experienced small to moderate decreases in physical (p = 0.004), role (p = 0.016) and emotional (p = 0.001) function at 6 weeks post-surgery, which resolved by 6–12 months. Conclusions: The global QoL of patients undergoing low-, intermediate- and high-SCS surgery improved at 12 months after surgery and was no worse in patients undergoing extensive surgery. Tweetable Abstract: Compared with surgery of lower complexity, extensive surgery does not result in poorer quality of life in patients with advanced ovarian cancer.
KW - extensive surgery
KW - ovarian cancer
KW - quality of life
KW - ultraradical surgery
U2 - 10.1111/1471-0528.17041
DO - 10.1111/1471-0528.17041
M3 - Article
C2 - 34865316
SN - 1470-0328
JO - BJOG : an international journal of obstetrics and gynaecology
JF - BJOG : an international journal of obstetrics and gynaecology
ER -
